CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- PositionReturn on equity is -496.1%, lower than 95% of its Biotechnology peers (median -21.7%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
611.85MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
2.22xvs all stocks
52-Week Change
133.58%vs all stocks
Market Capitalization
611.85MUSDvs all stocks (USD)
Enterprise Value
635.51MUSDvs all stocks (USD)
Forward P/E
-12.80xvs Biotechnology peers
Price to Book (MRQ)
31.49xvs Biotechnology peers
Enterprise to EBITDA
-12.17xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-108.43%vs Biotechnology peers
Return on Equity (TTM)
-496.15%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 17, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-52.23MUSDvs all stocks (USD)
Net Income (TTM)
-51.99MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-45.31MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-26.95MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-54.88MUSDvs all stocks (USD)
Pre-tax Income
-54.65MUSDFY2025 · Dec 31, 2025Net Income
-54.65MUSDFY2025 · Dec 31, 2025EBIT
-53.83MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-53.19MUSDFY2025 · Dec 31, 2025Research & Development
23.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
31.88MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
819.00KUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.25USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.25USDFY2025 · Dec 31, 2025Basic Shares Outstanding
43.59MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
43.59MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-54.65MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-46.28MUSDFY2025 · Dec 31, 2025Free Cash Flow
-46.29MUSDDerived from operating cash flow minus capital expenditure. This filing charges 228K of depreciation against 4K of capital expenditure, and its own free-cash-flow line reads -49.47M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
20.95MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-54.65MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
228.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.76MUSDFY2025 · Dec 31, 2025Other Non-cash Items
460.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
0.00USDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.08MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
0.00USDFY2025 · Dec 31, 2025Capital Expenditures
-4.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-24.75MUSDFY2025 · Dec 31, 2025Sale of Investments
30.87MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
6.11MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
5.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
50.14MUSDFY2025 · Dec 31, 2025Shares Outstanding
53.24MSharesUpdated Jul 17, 2026Shares Short
12.58MSharesUpdated Jul 17, 2026Short Ratio
4.92daysvs all stocks
Short % of Shares Outstanding
12.32%vs all stocks
% Held by Insiders
0.93%vs all stocks
% Held by Institutions
63.63%vs all stocks
Total Cash (MRQ)
29.27MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.2850USDUpdated Jul 17, 2026Total Debt (MRQ)
14.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.40xvs Biotechnology peers
Current Ratio (MRQ)
2.63xvs Biotechnology peers
Book Value per Share (MRQ)
0.2010USDUpdated Jul 17, 2026Total Assets
41.79MUSDvs all stocks (USD)
Total Current Assets
39.89MUSDFY2025 · Dec 31, 2025Total Liabilities
20.27MUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.90MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
11.19MUSDFY2025 · Dec 31, 2025Total Current Liabilities
9.08MUSDFY2025 · Dec 31, 2025Cash
639.00KUSDFY2025 · Dec 31, 2025Cash Equivalents
20.27MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
20.91MUSDFY2025 · Dec 31, 2025Other Short-term Investments
15.47MUSDFY2025 · Dec 31, 2025Accounts Payable
867.00KUSDFY2025 · Dec 31, 2025Short-term Debt
3.77MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.56MUSDFY2025 · Dec 31, 2025Long-term Debt
11.19MUSDFY2025 · Dec 31, 2025Common Stock (Book)
121.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-260.23MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
21.52MUSDvs all stocks (USD)
52-Week Low
2.37USDUpdated Jul 17, 202652-Week High
7.11USDUpdated Jul 17, 202652-Week Change
133.58%vs all stocks
Beta
2.22xvs all stocks
50-Day MA
5.47USDUpdated Jul 17, 2026200-Day MA
4.59USDUpdated Jul 17, 2026Avg 10-Day Volume
1.94MSharesUpdated Jul 17, 2026Avg 30-Day Volume
2.38MSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-1.07USDUpdated Jul 17, 2026Other Income / Expense
-444.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -496.1%, lower than 95% of its Biotechnology peers (median -21.7%)Significant
Return on equity: -4.96Industry median: -0.22Industry P5: -1.66Peers compared: 261
Return on assets is -108.4%, lower than 95% of its Biotechnology peers (median -20.1%)Significant
Return on assets: -1.08Industry median: -0.20Industry P5: -0.85Peers compared: 261
Debt-to-equity is 1.4×, higher than 95% of its Biotechnology peers (median 0.09×)Significant
Debt-to-equity: 1.40Industry median: 0.09Industry P95: 0.88Peers compared: 261
Price-to-book is 31.49×, higher than 95% of its Biotechnology peers (median 2.97×)Significant
Price-to-book: 31.49Industry median: 2.97Industry P95: 23.50Peers compared: 261
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.70
Altman Z-Score 6.03: safe zoneNotable
Altman Z-Score: 6.03
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Jinhe Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hainan Shuangcheng Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Seers Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allogene Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Scitop Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Kexing Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou AGS Medtech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule